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Abstract
Background Esophageal adenocarcinoma patients have limited treatment options. TGF-β can be upregulated in esophageal
adenocarcinoma, and blocking this pathway may enhance clinical response to PD-(L)1 inhibitors. Bintrafusp alfa is a firstin-class bifunctional fusion protein composed of the extracellular domain of the TGF-βRII receptor (a TGF-β “trap”) fused
to a human IgG1 mAb blocking PD-L1.
Objective The objective of this study was to investigate the efficacy and safety of bintrafusp alfa in patients with advanced,
post-platinum esophageal adenocarcinoma, unselected for PD-L1 expression.
Patients and Methods In this phase 1 study, patients with post-platinum, PD-L1–unselected esophageal adenocarcinoma
received bintrafusp alfa 1200 mg every 2 weeks until disease progression, unacceptable toxicity, or withdrawal. The primary
endpoint was confirmed best overall response per RECIST 1.1 by independent review committee (IRC).
Results By the database cutoff of 24 August 2018, 30 patients (80.0% had two or more prior anticancer regimens) received
bintrafusp alfa for a median of 6.1 weeks. The confirmed objective response rate (ORR) per IRC was 20.0% (95% CI 7.7–
38.6); responses lasted 1.3–8.3 months. Most responses (83.3%) occurred in tumors with an immune-excluded phenotype.
Investigator-assessed confirmed ORR was 13.3% (95% CI 3.8–30.7). Nineteen patients (63.3%) had treatment-related adverse
events: seven patients (23.3%) had grade 3 events; no grade 4 events or treatment-related deaths occurred.
Conclusions Bintrafusp alfa showed signs of clinical efficacy with a manageable safety profile in patients with heavily pretreated, advanced esophageal adenocarcinoma.
Clinical Trials Registration NCT02517398.

1 Background

In 2018, esophageal cancer caused approximately 500,000
deaths worldwide [1]. The prognosis of patients with esophageal cancer is poor, with age-standardized 5-year survival
rates ranging from 10 to 30% after correction for background
mortality [2]. The majority of patients have advanced disease at diagnosis, with 5-year survival rates below 10% [3].
Esophageal cancer comprises two subtypes: adenocarcinoma (AC) and squamous cell carcinoma (SCC). Although
SCC remains the most prevalent histological type of esophageal cancer, incidence rates are decreasing worldwide [1]. In
contrast, the incidence of AC is rapidly increasing in Western countries such as Australia, England, France, and the
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USA [1]. This observed increase is most likely due to the
escalating prevalence of risk factors for esophageal AC, such
as obesity and chronic gastroesophageal reflux disease [1, 4].
Genetic profiling has identified tumor-specific alterations
in esophageal AC affecting ERBB2, VEGFA, GATA4, and
GATA6, as well as genes involved in DNA hypermethylation,
but other factors in the tumor microenvironment (TME) are
also known to impact cancer [5–7]. Transforming growth
factor β (TGF-β) is one such factor in the TME. TGF-β is a
cytokine with highly diverse functions that can act in either
a tumor-suppressive or a tumor-promoting role, depending on the tumor type and stage, and genetic and/or epigenetic changes within the TGF-β pathway [8, 9]. Signaling
through the TGF-β pathway can enable cancer progression
and immune evasion in the TME through regulatory effects
on immune cells, and may also influence angiogenesis and
epithelial-to-mesenchymal transition (EMT) [9, 10]. Preclinical studies have shown that TGF-β can induce EMT in
Vol.:(0123456789)
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Key Points
Bintrafusp alfa is a first-in-class bifunctional fusion
protein that was designed for co-localized, simultaneous inhibition of two nonredundant immunosuppressive
pathways, TGF-β and PD-L1, within the tumor microenvironment.
Treatment with bintrafusp alfa had a manageable safety
profile and demonstrated clinical activity in patients with
advanced, post-platinum esophageal adenocarcinoma
from a phase 1 expansion cohort.
These results, along with those reported in the accompanying article from an expansion cohort of Asian patients
with pretreated, PD-L1-unselected esophageal squamous
cell carcinoma in a separate phase 1 study, support further clinical investigation of bintrafusp alfa in esophageal
cancer.
esophageal AC cell lines and that expression of TGF-β correlated with the expression of EMT-related genes [11, 12].
Furthermore, elevated expression of TGF-β in esophageal
AC has been associated with advanced stages of disease, and
correlates with poor overall survival (OS) [13].
Antibodies that target immune checkpoints have emerged
in recent years as a novel therapeutic approach for the
treatment of a wide range of cancers. The efficacy of antiPD-1 agents has been investigated in advanced, pretreated
esophageal cancer; however, these studies often had low
enrollment of patients with esophageal AC [14, 15]. In the
KEYNOTE-180 and KEYNOTE-181 clinical trials, pembrolizumab showed an objective response rate (ORR) of 5%
in patients with PD-L1-unselected (all-comer), 3% in those
with PD-L1-negative (combined positive score [CPS] < 10),
and 18% in those with PD-L1-positive (CPS ≥ 10) esophageal AC [14, 15].
Preclinical studies have suggested that the efficacy of antiPD-(L)1 agents may improve with the addition of TGF-β
blockade [16–19]. Bintrafusp alfa is a first-in-class bifunctional fusion protein composed of the extracellular domain
of the human TGF-β receptor II (TGF-βRII or TGF-β “trap”)
fused via a flexible linker to C-terminus of each heavy chain
of IgG1 antibody blocking PD-L1 (anti-PD-L1) [20]. Bintrafusp alfa is designed for co-localized, simultaneous inhibition of two nonredundant immunosuppressive pathways
(TGF-β and PD-L1) within the TME [20]. This may provide
an enhanced treatment effect, potentially improving clinical
benefit compared with anti-PD-(L)1 monotherapies [20–22].
Clinical data from two phase 1 studies of bintrafusp alfa
(NCT02517398 and NCT02699515) have demonstrated a
manageable safety profile and early signs of clinical efficacy

in patients with heavily pretreated advanced solid tumors
[23–25]. Here we report results from an expansion cohort of
the phase 1 study, which investigated the efficacy and safety
of bintrafusp alfa in patients with advanced, post-platinum
esophageal AC, unselected for PD-L1 expression.

2 Patients and Methods
2.1 Study Design and Participants
This phase 1, open-label trial investigated the safety and
efficacy of bintrafusp alfa in patients with heavily pretreated
solid tumors and included multiple expansion cohorts in specific tumor types (NCT02517398). Patients were screened
across the Asia-Pacific region, Europe, Canada, and the
USA.
Eligible patients had histologically confirmed recurrent
or metastatic, unresectable (stage III/IV) esophageal AC and
measurable disease by Response Evaluation Criteria in Solid
Tumors version 1.1 (RECIST 1.1). Patients were at least 18
years old and must have received at least one prior platinumbased regimen. Patients with HER2-positive tumors must
have received prior trastuzumab. Other inclusion criteria
included Eastern Cooperative Oncology Group (ECOG)
performance status of 0 or 1, life expectancy of ≥ 12 weeks,
and adequate renal, hepatic, and hematological function.
Prior to enrollment, tumor samples (archival material or
fresh biopsies obtained within 28 days) were collected from
each patient; however, no selection was made on the basis
of PD-L1 expression or other biomarkers. Prior therapy with
immune checkpoint inhibitors was not permitted.

2.2 Treatment and Assessments
Patients received bintrafusp alfa at the recommended phase 2
dose of 1200 mg intravenously over 1 h once every 2 weeks
until confirmed progressive disease, unacceptable toxicity,
or trial withdrawal [26]. A flat dose of 1200 mg every 2
weeks was selected as the recommended phase 2 dose of
bintrafusp alfa based on safety/tolerability, pharmacokinetic,
and pharmacodynamic data, as well as preliminary population pharmacokinetics and exposure-response modeling of
phase 1 data [26, 27]. The planned duration of treatment for
patients who achieved a best overall response of complete
response, partial response, or stable disease was 12 months.
If the investigator believed that a patient may benefit, additional treatment beyond 12 months could be possible. Dose
reductions were not permitted. Tumor responses were monitored by imaging every 6 weeks during the first year and
every 12 weeks thereafter. Scans were reviewed by an independent review committee to assess disease response. Efficacy and safety were analyzed in all patients who received at
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least one dose of bintrafusp alfa. Adverse events (AEs) were
monitored throughout treatment and were assessed according to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 4.03. An
additional safety follow-up visit was planned 28 days after
the last study dose or before the start of a new treatment
(whichever occurred first). Treatment-related AEs (TRAEs)
continued to be evaluated 10 weeks post-treatment. Any AE
that was believed to be a potential immune-related or potential TGF-β-related event was considered an AE of special
interest. Immune-related AEs (irAEs) were identified using
a preselected list of terms from the Medical Dictionary for
Regulatory Activities version 21.0.

2.3 Endpoints
The primary endpoint was confirmed best overall response
according to RECIST 1.1 as adjudicated by the independent review committee and evaluated by the confirmed ORR;
key secondary endpoints included the safety of bintrafusp
alfa and best overall response per investigator assessment.
Other efficacy measures included duration of response, disease control rate (DCR), progression-free survival (PFS),
and OS. The evaluation of potential predictive biomarkers
was an exploratory endpoint.

2.4 Exploratory Endpoints
PD-L1 expression was detected by immunohistochemistry
staining of formalin-fixed, paraffin-embedded tumor tissue
using an anti-PD-L1 antibody clone 73-10 (Dako PD-L1
IHC 73-10 pharmDx; Dako, Carpinteria, CA, USA). PD-L1
expression was measured on tumor cells and on cells of the
TME. Data herein are reported based on the percentage of
tumor cells expressing PD-L1. A threshold of 1% was used
to characterize tumors as either PD-L1 positive (≥ 1%) or
PD-L1 negative (< 1%).
RNA sequencing (RNAseq) was also performed to assess
the correlation between specific tumor characteristics and
response to bintrafusp alfa. RNAseq used formalin-fixed,
paraffin-embedded archival tumor samples and was performed by Asuragen (Austin, TX, USA) using standard
protocols based on ribosomal depletion. Resulting sequencing reads were aligned against the Ensembl 75 human
genome (GRCh37 February 2014) with Bowtie2 version
2.2.3 (Johns Hopkins University, Baltimore, MD, USA)
[28]. Gene expression was determined using RSEM version
1.2.31 and Ensembl gene annotations, and hypothesis testing was performed by comparing RSEM-computed expected
counts [29]. Transcript-per-million values were upper-quartile normalized and log transformed for further analysis. To
test whether TGFB1, TGFB2, and TGFB3 gene expression
was higher in this cohort than in other expansion cohorts

across phase 1 trials of bintrafusp alfa (NCT02517398
and NCT02699515), we applied limma + voom, modeling
expression as a function of indication [30]. The analysis
included all patient samples that passed quality control (N
= 537, including 27 esophageal AC samples) and tested all
genes with ≥ 10 reads in ≥ 20 samples. We report p values
for differential expression after adjustment for testing of all
genes.
Tumor mutation count was measured by an RNAseqbased variant calling that used tumor RNAseq data combined with germline, normal whole-exome sequencing to
produce a set of tumor-specific mutations. Tumor samples
were sequenced at 2 × 50 to a target of 108 read pairs with
an Illumina HiSeq System (Illumina, San Diego, CA, USA).
Whole-exome sequencing was performed by Expression
Analysis (Research Triangle Park, NC, USA) using matched
peripheral blood samples and an Agilent SureSelect Human
All Exon V5 kit (Agilent Technologies, Santa Clara, CA,
USA). Sequencing was done on an Illumina HiSeq System with a target of 100 × coverage. Sequencing reads
were mapped to hg19 and the Ensembl gene annotations
(ensGene; University of California, Santa Cruz, CA, USA)
using RNA-STAR version 2.5.0b; whole-exome reads were
mapped to hg19 using BWA-MEM version 0.7.12 [31, 32].
Mutation calling was performed on paired BAM files using
VarDictJava version 1.4.2 [33]. Results were annotated using
Ensembl Variant Effect Predictor version 85 to determine the
location and type of mutation [34]. Tumor mutation count
was defined for each patient as the total count of all missense
mutations discovered for that sample.
Immune phenotype was determined from tumor samples
using available immunohistochemistry data (PD-L1 stain
and negative control) and hematoxylin and eosin stain. A
pathologist who was masked to the response data scored the
scanned images and determined the corresponding immune
phenotype using an exploratory classification system
[35–38]. Inflamed samples had immune cells in direct physical contact with tumor cells. Immune-excluded samples had
≥ 1% of the tumor stroma area populated by lymphocytes
where they may be near tumor cells without infiltration and
infrequent physical contact between lymphocytes and tumor
cells. Immune-desert samples had < 1% of the tumor stroma
area populated by lymphocytes, with no dense immune cell
infiltrates and no contact between immune and tumor cells.

2.5 Statistical Analysis
Thirty patients were planned for this expansion cohort to
give the study approximately 87% power to rule out ≤ 15%
ORR (null hypothesis) when the true ORR is 35% with
1-sided α = 0.1. The analysis presented here was performed
based on a data cutoff approximately 1.5 years after the
last patient enrolled in the study. The confirmed ORR was
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defined as the proportion of patients achieving a confirmed
complete or partial response. The uncertainty of the estimates was assessed by a two-sided 95% Clopper-Pearson
CI. DCR was defined as the proportion of patients with a
best overall response of complete response, partial response,
stable disease, or non-complete response/non-progressive
disease. PFS and OS time were analyzed using the KaplanMeier method.

3 Results
3.1 Patient Demographics and Characteristics
Between 12 September 2016, and 31 January 2017, 47
patients with advanced, post-platinum esophageal AC who
had disease progression after at least one prior line of treatment were screened; 30 patients from 21 centers met the
eligibility criteria and were treated with bintrafusp alfa. Of
these patients, 14 (46.7%) were from the USA, ten (33.3%)
were from Europe, five (16.7%) were from Australia, and
one (3.3%) was from Taiwan. The median age was 61
(range 30–80) years, and most patients had an ECOG performance status of 1 (n = 25 [83.3%]). This was a heavily pretreated population; 80.0% of patients had received
at least two prior anticancer therapy regimens, and 36.7%
of patients had received at least two prior lines of therapy
for locally advanced or metastatic disease. Most tumors (n
= 20 [66.7%]) were negative for PD-L1 expression, with
nine (30.0%) being positive and one (3.3%) that was not
evaluable. Detailed baseline characteristics are described in
Table 1.
As of 24 August 2018, 30 patients received bintrafusp
alfa for a median duration of 6.1 (range 2.0–55.7) weeks.
The Kaplan-Meier estimate of median duration of follow-up
since first dose was 86.1 (range 1.3–91.4) weeks. All patients
had discontinued treatment at the time of data cutoff. Reasons for discontinuation were disease progression (n = 19
[63.3%]), AEs (n = 8 [26.7%]), death (n = 2 [6.7%]), and
other reasons (n = 1 [3.3%]; patient completed 12 months’
treatment). Following treatment with bintrafusp alfa, eight
patients (26.7%) received at least one type of subsequent
anticancer treatment, of whom six patients received cytotoxic therapy.

3.2 Efficacy
Responses occurred in six patients per independent
review committee assessment, all of which were partial
responses (confirmed ORR, 20.0% [95% CI 7.7–38.6])
(Table 2, Fig. 1a). The median duration of response was 4.3
(range 1.3–8.3) months (Table 2, Fig. 1b). An additional
four patients had stable disease (DCR, 33.3% [95% CI

Table 1  Patient baseline and disease characteristics
Characteristic

N = 30

Median age, years (range)
Sex, n (%)
Male
Female
ECOG performance status, n (%)
0
1
Number of prior anticancer therapy regimens, n (%)
1
2
≥3
Number of prior lines of therapy for locally advanced or
metastatic disease, n (%)
0
1
≥2
Type of prior anticancer therapy for locally advanced or
metastatic disease, n (%)a
Cytotoxic therapy
Monoclonal antibodies therapy
Small molecules
Tumor cell PD-L1 expression, n (%)b
Positive
Negative
Not evaluable

61 (30–80)
28 (93.3)
2 (6.7)
5 (16.7)
25 (83.3)
6 (20.0)
14 (46.7)
10 (33.3)

5 (16.7)
14 (46.7)
11 (36.7)

25 (83.3)
6 (20.0)
2 (6.7)
9 (30.0)
20 (66.7)
1 (3.3)

ECOG Eastern Cooperative Oncology Group
a

b

Patients may be included in more than one category

A threshold of 1% was used to characterize tumors as either PD-L1
positive (≥ 1%) or negative (< 1%) using an anti-PD-L1 antibody
clone 73-10

17.3–52.8]). The investigator-assessed confirmed ORR was
13.3% (95% CI 3.8–30.7); agreement between independent review committee and investigator-assessed responses
is presented in the Online Supplementary Material (OSM),
Table S1.
Median PFS was 1.3 months (95% CI 1.0–5.3) by independent review committee, with a 6-month rate of 25.9%
(95% CI 11.5–43.1) (Fig. 2a). Similar median PFS was
observed by investigator assessment (1.3 months [95% CI
1.1–5.3]) (OSM Fig. S1). Median OS was 3.4 months (95%
CI 2.5–10.3), with respective 6- and 12-month OS rates of
39.7% (95% CI 22.0–57.0) and 32.1% (95% CI 16.0–49.5)
(Fig. 2b).

3.3 Biomarker Analyses
Response to bintrafusp alfa was observed in patients with
PD-L1-positive and PD-L1-negative tumors (Table 2).
PD-L1 expression in the TME was also evaluated, and
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Table 2  Treatment response to bintrafusp alfa
Efficacy (N = 30)
Confirmed best overall response, n (%)
Complete response
Partial response
Stable disease
Progressive disease
Not evaluable
Confirmed ORR, n (%)
95% CI
DCR, n (%)
95% CI
Median duration of response, months (range)
ORR by tumor cell PD-L1 expression, n/N (%)a
Positive
Negative
Not evaluable

Independent review committee

Investigator

0
6 (20.0)
4 (13.3)
15 (50.0)
5 (16.7)
6 (20.0)
7.7–38.6
10 (33.3)
17.3–52.8
4.3 (1.3–8.3)

0
4 (13.3)
7 (23.3)
12 (40.0)
7 (23.3)
4 (13.3)
3.8–30.7
11 (36.7)
19.9–56.1
NR (3.6–12.6)

1/9 (11.1)
4/20 (20.0)
1/1 (100)

0/9 (0)
4/20 (20.0)
0/1 (0)

DCR disease control rate, NR not reached, ORR objective response rate
a

A threshold of 1% was used to characterize tumors as either PD-L1 positive (≥ 1%) or negative (< 1%) using an anti-PD-L1 antibody clone
73-10

responses to bintrafusp alfa, as determined by either independent review committee or investigator assessment, were
observed independently of PD-L1 expression (data not
shown). The majority of responses (n = 5 [83.3%]) occurred
in patients with an immune-excluded phenotype (Fig. 3a).
The ORR by independent review committee was 12.5% in
the inflamed, 27.8% in the immune-excluded, and 0% in the
immune-desert phenotype. However, responses to bintrafusp
alfa were observed independently of tumor mutation count,
as well as expression of genes associated with an active
immune pathway (such as CD8A, CD8B, and IFNG) or
TGF-β activation (such as TGFB1, TWIST1, VIM) (Fig. 1a,
Fig. 3b–g). Further investigation revealed different average
levels of tumor TGFB1 expression between patients with
esophageal AC in this study and patients with esophageal
SCC in a separate phase 1 study of bintrafusp alfa [39], with
41.8% lower expression in AC than in SCC (false discovery
rate–adjusted p < 0.002). TGFB3 expression was also lower
in patients with esophageal AC than in those with esophageal SCC, but the difference was not significant (false discovery rate–adjusted p = 0.426). In contrast, TGFB2 expression was 96.6% higher in esophageal AC than in esophageal
SCC (false discovery rate–adjusted p = 0.049) (OSM Fig.
S2). When compared across patients from phase 1 trials of
bintrafusp alfa, TGFB expression levels in tumor samples
from patients with esophageal AC were not significantly different from those from patients with other tumor types with
various histologies (false discovery rate–adjusted p = 0.465
[TGFB1]; p = 0.989 [TGFB2]; p = 0.082 [TGFB3]).

3.4 Safety
Among the 30 patients, 19 (63.3%) experienced a TRAE of
any grade, of which diarrhea, pruritus (n = 4 [13.3%] each),
and asthenia (n = 3 [10.0%]) were most common (Table 3).
Seven patients (23.3%) experienced at least one grade 3
TRAE, including anemia (n = 2 [6.7%]), Bowen’s disease
(also known as SCC in situ), cancer pain, gastritis hemorrhagic, hypophysitis, hypopituitarism, rash generalized, and
SCC of skin (n = 1 [3.3%] each). No grade 4 TRAEs or
treatment-related deaths occurred. TRAEs led to permanent
discontinuation in two patients (6.7%). One patient developed a cough 2 days after the first dose of bintrafusp alfa.
The cough persisted, and 4 weeks later the patient developed
dyspnea (grade 1), determined as treatment related by the
investigator. Imaging showed lymphangitis carcinomatosis
and findings that were suggestive of multiple small lung
metastases. Bintrafusp alfa was permanently discontinued,
and the patient withdrew from the study due to confirmed
disease progression. The second patient permanently discontinued treatment due to grade 3 gastritis hemorrhagic,
also determined as treatment related by the investigator.
This patient had a history of pseudoaneurysm of the celiac
trunk and developed treatment-emergent gastritis hemorrhagic 3 weeks after the first study dose of bintrafusp alfa (9
days after the preceding dose). Gastrointestinal bleeding of
unknown origin was found upon hospitalization. This event
improved after 3 weeks following blood transfusions and
treatment with parenteral tranexamic acid, somatostatin, and
proton pump inhibitors. Following resolution of the AE and

B. Tan et al.

Fig. 1  Tumor response to bintrafusp alfa assessed by independent review. a Best change in sum of diameters and tumor mutation
count. A threshold of 1% was used to characterize tumors as either
PD-L1 positive (≥ 1%) or negative (< 1%) using an anti-PD-L1 antibody clone 73-10. One patient had non-evaluable PD-L1 expression.
b Time to and duration of response. The upper dashed line represents
progression at 20% increase in size of target lesions, and the lower

dashed line represents the RECIST boundary for partial response
at 30% decrease in size of target lesions. Six patients are not shown
because they had no post-baseline assessments due to death within
6 weeks after starting treatment (n = 2), had no baseline and postbaseline target lesion measurement (n = 1), or due to other reasons (n
= 3). aTumor mutation count data unavailable. NE not evaluable, PD
progressive disease, PR partial response, SD stable disease

reinitiation of bintrafusp alfa, grade 3 gastritis hemorrhagic
recurred and was determined to be related to bintrafusp alfa.
The patient permanently discontinued study treatment and
received the same medical management that was previously
used to treat their gastritis hemorrhagic for 3 weeks until
the event resolved. Seven patients (23.3%) had irAEs, none

of which were above grade 3 or led to discontinuation of
treatment (OSM Table S2). No patient experienced a grade
≥ 3 infusion-related reaction that was assessed by the investigator as being related to bintrafusp alfa. Potentially TGFβ-related skin lesions were reported in two patients (6.7%),
one of whom experienced multiple events (OSM Table S2).
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Fig. 2  Survival outcomes. Kaplan–Meier survival curves for a independent review committee-assessed progression-free survival (PFS) and b
overall survival (OS)

These skin lesions were generally managed well with complete excision when needed and did not lead to treatment
discontinuation.

4 Discussion
In this phase 1, dose-expansion cohort of 30 patients
with advanced, post-platinum esophageal AC, bintrafusp
alfa showed evidence of clinical activity with an ORR of
20.0% per independent review committee assessment and
a 12-month OS rate of 32.1% in the overall, PD-L1-unselected cohort. Additionally, responses were independent of
PD-L1 expression on tumor cells or on cells of the TME.
Phase 2 and 3 studies of pembrolizumab showed ORRs
that ranged from 3 to 18% and 12-month OS rates that were
between 22 and 24% in patients with pretreated esophageal
AC, depending on PD-L1 expression [14, 15]. However, the

results observed here for bintrafusp alfa cannot be directly
compared with those reported for pembrolizumab because of
key differences in study design. Larger studies are needed to
confirm the impact of PD-L1 expression on clinical activity
with bintrafusp alfa in esophageal AC.
Results of exploratory analyses showed that response to
bintrafusp alfa was independent of tumor mutation count.
Patients in this esophageal AC cohort had lower mutation
counts than patients with esophageal SCC enrolled in a
different phase 1 study of bintrafusp alfa (NCT02699515)
[39]. Furthermore, the average expression levels of TGFB1,
TGFB2, and TGFB3 in tumor samples from patients in this
study were similar to those from patients with other tumors
across phase 1 studies of bintrafusp alfa; however, the levels
of TGFB1 and TGFB2 were significantly different (lower
and higher, respectively) than those observed in an esophageal SCC cohort of the separate phase 1 study of bintrafusp
alfa. Previous reports have shown a link between TGF-β

B. Tan et al.

Fig. 3  Exploratory biomarker analysis by confirmed best overall
response to bintrafusp alfa per independent review committee assessment. a Immune phenotype analysis; three patients with immune
phenotypes of indeterminate (n = 1) or not annotated (n = 2) are not
shown. b Gene expression analysis; three patients with confirmed
best overall responses of partial response, stable disease, and progres-

sive disease (n = 1, each) were not included in the RNAseq analysis
due to failing QC or lack of RNAseq data. IFNG interferon gamma,
NE not evaluable, PD progressive disease, PR partial response, SD
stable disease, TGFB1 transforming growth factor beta 1, TPM transcript per million, TWIST1 twist family bHLH transcription factor 1,
VIM vimentin
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Table 3  TRAEs occurring at any grade in ≥ 5% of patients or at
grade 3 severity, and any AEs of special interest
Preferred term, n (%)

TRAEs
TRAE
Diarrhea
Pruritus
Asthenia
Anemia
Rash generalized
Alanine aminotransferase increased
Aspartate aminotransferase increased
Dyspnea
Fatigue
Hyperthyroidism
KA
Nausea
Rash
Rash, macular
Bowen’s diseaseb
Cancer pain
Gastritis hemorrhagic
Hypophysitis
Hypopituitarism
SCC of skin
Any AE of special interest
Skin lesionsc
Any irAE
Immune-related rash
Immune-related pituitary dysfunction
Immune-related pneumonitis
Immune-related thyroid disorders

N = 30
Any grade

Grade 3a

19 (63.3)
4 (13.3)
4 (13.3)
3 (10.0)
2 (6.7)
2 (6.7)
2 (6.7)
2 (6.7)
2 (6.7)
2 (6.7)
2 (6.7)
2 (6.7)
2 (6.7)
2 (6.7)
2 (6.7)
1 (3.3)
1 (3.3)
1 (3.3)
1 (3.3)
1 (3.3)
1 (3.3)

7 (23.3)
0
0
0
2 (6.7)
1 (3.3)
0
0
0
0
0
0
0
0
0
1 (3.3)
1 (3.3)
1 (3.3)
1 (3.3)
1 (3.3)
1 (3.3)

2 (6.7)
7 (23.3)d
5 (16.7)
1 (3.3)
1 (3.3)
1 (3.3)

1 (3.3)
2 (6.7)
1 (3.3)
1 (3.3)
0
0

AE adverse event, irAE immune-related adverse event, KA keratoacanthoma, SCC squamous cell carcinoma, TRAE treatment-related
adverse event
a

b
c

No patients experienced a grade > 3 TRAE
Also known as SCC in situ

Includes actinic keratosis, basal cell carcinoma, Bowen’s disease,
hyperkeratosis, KA, lip SCC, and SCC of skin NCI-CTCAE v4.03
preferred terms

d

Three patients experienced multiple different irAEs

and immune phenotype, suggesting TGF-β can restrict T-cell
infiltration in the TME and limit antitumor immunity [16,
40]. In preclinical studies, the combined use of a TGF-β
inhibitor with a PD-L1 inhibitor significantly increased
tumor-infiltrating T cells and significantly reduced tumor
burden in mouse models of immune-excluded tumors [16].
Interestingly, all but one response occurred in immuneexcluded tumors in this esophageal AC cohort. Similar

results were also observed in patients with esophageal SCC
from the other study, in which responses were seen exclusively in immune-excluded tumors [39]. Taken together, the
results of the exploratory analyses did not identify predictive biomarkers of response to bintrafusp alfa in this small
cohort.
Treatment with bintrafusp alfa was well tolerated in this
patient population, with no grade 4 TRAEs or treatmentrelated deaths. The safety profile, including incidence of
irAEs, was similar to that seen with checkpoint inhibitors,
except for potentially TGF-β-related skin lesions, which
were reported in two patients [14, 15, 41–48]. These AEs
were generally managed well and did not lead to discontinuation from the trial. Importantly, skin lesions, such as
keratoacanthomas, are anticipated AEs for TGF-β inhibition
[49]. The overall safety profile reported here for bintrafusp
alfa in esophageal AC was consistent with those previously observed with bintrafusp alfa treatment in other solid
tumors, including esophageal SCC [23, 24, 39].
Limitations of this study include the small enrollment
size and the lack of a comparator arm, which preclude any
definitive conclusions regarding comparisons of bintrafusp
alfa with other available treatment options.
The clinical activity and manageable safety profile
observed in this study of heavily pretreated patients with
esophageal AC suggest that bintrafusp alfa could provide a
novel treatment approach for these patients. Further clinical
investigation of bintrafusp alfa in esophageal cancer is warranted based upon these results.
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